Pharmacovigilance

PHARMACOVIGILANCE SYSTEM DEVELOPMENT

Currently available only in Poland, INAR leads a full pharmacovigilance (PhV) system. We are able to create and oversee a complex Pharmacovigilance system that is compliant with the Pharmaceutical Law and the European Union guidelines. Our broad range of services include:

PhV system development

QUALIFIED PERSON FOR PHARMACOVIGILANCE (QPPV) SERVICES

The Qualified Person Responsible for Pharmacovigilance (QPPV) is the person responsible for establishing and maintaining a PhV system, including all legally required activities related to pharmacovigilance. Our QPPV services are performed in accordance with the requirements of Article 23 of Regulation (EC) No 726/2004.

QPPV 2

CONTINUOUS MONITORING OF GLOBAL AND LOCAL SCIENTIFIC AND MEDICAL LITERATURE

INAR offers continuous monitoring of global and local scientific and medical literature. This service is conducted according to the guidance of Good Pharmacovigilance Practice (GVP).

According to the guidelines:  “The scientific and medical literature is a significant source of information for the monitoring of the safety profile and of the risk-benefit balance of medicinal products, particularly in relation to the detection of new safety signals or emerging safety issues. Marketing authorization holders are therefore expected to maintain awareness of possible publications through a systematic literature review of widely used reference databases (e.g. Medline, Excerpta Medica or Embase) no less frequently than once a week. In addition, marketing authorization holders should have procedures in place to monitor scientific and medical publications in local journals in countries where medicinal products have a marketing authorization, and to bring them to the attention of the Company safety department as appropriate.” (GVP module VI)

literature

At INAR, we go beyond identification of individual case safety reports by using a unique approach that identifies all articles containing information regarding safety issues of the monitored substance (i.e. interactions, exposure during pregnancy, preclinical safety data), in addition to articles containing the minimum information for reporting. This service also includes formation of a Report, presented in tabular form and grouped in terms of safety issues. The scope of monitoring the extent of categorisation, and the resulting report itself, can be adapted to individual Company needs and requirements.

Pharmacovigilance EN

Free 60 day trial

To view advantages of this service, we encourage to use our free 60-day trial by ordering at  qppv@inar.pl or by phone at +48 502 315 778.

The trial version offers all the same capabilities and functionalities as the payable version.